Showing 3 posts of 3 posts found.


Bayer’s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer at risk of metastasis

October 23, 2020
Medical Communications, Sales and Marketing Bayer, NCIE, Nubeqa, pharma

NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for …

Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer

March 31, 2020
Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer

The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …


Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer

July 31, 2019
Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer

The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …

Latest content